Table 1:
Clinical and imaging data of patients with low-grade gliomas demonstrating increased contrast enhancement
| Clinical Information | No. of Patients |
|---|---|
| Sex | |
| Female | 33 (34.4%) |
| Male | 63 (65.6%) |
| Age range (yr) | |
| 20–39 | 35 (36.5%) |
| 40–59 | 47 (49.0%) |
| Older than 60 | 14 (14.5%) |
| KPS | |
| ≥90 | 74 (77.1%) |
| ≤80 | 22 (22.9%) |
| Histologic subtype | |
| Diffuse astrocytoma | 30 (31.3%) |
| Oligoastrocytoma | 27 (28.1%) |
| Oligodendroglioma | 39 (40.6%) |
| IDH1 mutation | |
| Wild-type | 7 (7.3%) |
| Mutant | 61 (63.5%) |
| Not available | 28 (29.2%) |
| Baseline residual tumor | |
| Yes | 81 (84.4%) |
| No | 15 (15.6%) |
| Disease duration | |
| <2 years | 10 (10.4%) |
| 2–5 years | 35 (36.5%) |
| 5–10 years | 25 (26.0%) |
| >10 years | 26 (27.1%) |
| Adjuvant therapy | |
| RT | 75 (78.1%) |
| Carmustine implant | 9 (9.4%) |
| Temozolomide | 16 (16.7%) |
| Post-RT duration | |
| <6 months | 2 (2.7%) |
| 6–12 months | 5 (6.7%) |
| 12–24 months | 9 (12%) |
| >24 months | 59 (78.6%) |
| Whole tumor size | |
| <4 cm2 | 17 (17.7%) |
| 4–16 cm2 | 45 (46.9%) |
| >16 cm2 | 34 (35.4%) |
| Contrast enhancement size | |
| <4 cm2 | 37 (38.5%) |
| 4–16 cm2 | 36 (37.5%) |
| >16 cm2 | 23 (24.0%) |
| Tumor grade | |
| II | 42 (43.8%) |
| III | 27 (28.1% |
| IV | 27 (28.1%) |
Note:—RT indicates radiation therapy; KPS, Karnofsky Performance Scale.